Favorable response to combination treatment of cimetidine, cyclooxygenase-2 inhibitor and renin-angiotensin system inhibitor in metastatic renal cell carcinoma: Report of three cases

International Journal of Urology

Volumn 15, Issue 9, 2008, Pages 848-850

  Tatokoro, Manabu ^a,b   Fujii, Yasuhisa ^a,c   Kawakami, Satoru ^a,c   Fukui, Naotaka ^b   Komai, Yoshinobu ^a,c   Saito, Kazutaka ^a,b   Koga, Fumitaka ^a   Morimoto, Shinji ^b   Fukui, Iwao ^c   Kihara, Kazunori ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b TSUCHIURA KYODO GENERAL HOSPITAL   (Japan)

^c CANCER INSTITUTE HOSPITAL   (Japan)

Author keywords

Cimetidine; COX 2 inhibitors; Metastasis; Renal cell carcinoma; Renin angiotensin system inhibitors

Indexed keywords

ALPHA INTERFERON; ANGIOTENSIN RECEPTOR ANTAGONIST; CANDESARTAN HEXETIL; CIMETIDINE; CYCLOOXYGENASE 2 INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ETODOLAC; INTERLEUKIN 2; MELOXICAM; PERINDOPRIL;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; CANCER REGRESSION; CANCER STAGING; CASE REPORT; CLEAR CELL CARCINOMA; CLINICAL FEATURE; COMBINATION CHEMOTHERAPY; HUMAN; KIDNEY CARCINOMA; KIDNEY METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANGIOTENSINS; CARCINOMA, RENAL CELL; CIMETIDINE; CYCLOOXYGENASE 2 INHIBITORS; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; RENIN;

EID: 51349138395     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2008.02102.x     Document Type: Article

References (11)

1. Vogl UM, Zehetgruber H, Dominkus M et al. Prognostic factors in metastatic renal cell carcinoma: Metastasectomy as independent prognostic variable. Br. J. Cancer 2006 95 : 691 98.
2. Campbell SC, Novick AC, Bukowski RM. Renal tumors. In : Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA (eds). Campbell's Urology, vol. 2, chapt. 47, 9th edn. W.B. Saunders Co., Philadelphia, PA, 2007 1567 637.
3. Rini BI, Weinberg V, Dunlap S et al. Maximal COX-2 immunostaining and clinical response to celecoxib and interferon alpha therapy in metastatic renal cell carcinoma. Cancer 2006 106 : 566 75.
4. Yoshino S, Okabe T. Advanced renal cell carcinoma in which a combination of IFN-alpha and meloxicam was thought to be effective. Int. J. Urol. 2003 10 : 52 5.
5. Wang SR, Zweiman B. Histamine suppression of human lymphocyte responses to mitogens. Cell. Immunol. 1978 36 : 28 36.
6. Inhorn L, Williams SD, Nattam S, Stephens D. High-dose cimetidine for the treatment of metastatic renal cell carcinoma. A Hoosier Oncology Group study. Am. J. Clin. Oncol. 1992 15 : 157 9.
7. Nagano T, Matsuda H, Park YC, Kurita T. Successful treatment of metastatic renal cell carcinoma with cimetidine-report of two cases. Nippon Hinyokika Gakkai Zasshi 1996 87 : 1201 4.
8. Uemura H, Ishiguro H, Kubota Y. Pharmacology and new perspectives of angiotensin II receptor blocker in prostate cancer treatment. Int. J. Urol. 2008 15 : 19 26.
9. Heffelfinger SC. The renin angiotensin system in the regulation of angiogenesis. Curr. Pharm. Des. 2007 13 : 1215 29.
10. Miyajima A, Kosaka T, Asano T et al. Angiotensin II type I antagonist prevents pulmonary metastasis of murine renal cancer by inhibiting tumor angiogenesis. Cancer Res. 2002 62 : 4176 9.
11. Lokich J. Spontaneous regression of metastatic renal cancer. Case report and literature review. Am. J. Clin. Oncol. 1997 20 : 416 8.